These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32641110)

  • 1. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Takai Y; Yamada K; Tsuchida T; Otani N; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T
    BMC Pharmacol Toxicol; 2020 Jul; 21(1):50. PubMed ID: 32641110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced loading regimen of teicoplanin is necessary to achieve therapeutic pharmacokinetics levels for the improvement of clinical outcomes in patients with renal dysfunction.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Doita A; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Ikeuchi H; Uchino M; Kimura T
    Eur J Clin Microbiol Infect Dis; 2016 Sep; 35(9):1501-9. PubMed ID: 27278654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus infection: A systematic review and meta-analysis.
    Hanai Y; Takahashi Y; Niwa T; Mayumi T; Hamada Y; Kimura T; Matsumoto K; Fujii S; Takesue Y
    J Clin Pharm Ther; 2021 Jun; 46(3):622-632. PubMed ID: 33547647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal teicoplanin loading regimen to rapidly achieve target trough plasma concentration in critically ill patients.
    Li H; Gao L; Zhou L; Wang Y; Li Q; Wang J; Chen T; Zhang Y; Wang T; Shi Q
    Basic Clin Pharmacol Toxicol; 2020 Mar; 126(3):277-288. PubMed ID: 31608579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy.
    Kim SH; Kang CI; Huh K; Cho SY; Chung DR; Lee SY; Kim YJ; Peck KR
    Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2113-2120. PubMed ID: 31372903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced loading dose of teicoplanin for three days is required to achieve a target trough concentration of 20 μg/mL in patients receiving continuous venovenous haemodiafiltration with a low flow rate.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Yamada K; Tsuchida T; Otani N; Ide T; Takeda K; Nishi S; Takahashi Y; Ishihara M; Takubo S; Ikeuchi H; Uchino M; Kimura T
    J Infect Chemother; 2022 Feb; 28(2):232-237. PubMed ID: 34844858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections.
    Matsumoto K; Kanazawa N; Ikawa K; Fukamizu T; Shigemi A; Yaji K; Shimodozono Y; Morikawa N; Takeda Y; Yamada K
    J Infect Chemother; 2010 Jun; 16(3):193-9. PubMed ID: 20195882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose regimen to achieve novel target trough concentration in teicoplanin.
    Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Komatsu M; Tsuchida T; Takahashi Y; Ishihara M; Kimura T; Uchino M; Ikeuchi H
    J Infect Chemother; 2014 Jan; 20(1):43-7. PubMed ID: 24462424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of initial loading procedure for teicoplanin in critically ill patients with severe infections.
    Matsumoto K; Kanazawa N; Watanabe E; Yokoyama Y; Fukamizu T; Shimodozono Y; Maeda C; Yasuda T; Kakihana Y; Ikawa K; Morikawa N; Takeda Y
    Biol Pharm Bull; 2013; 36(6):1024-6. PubMed ID: 23727923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Possibility of Poor Outcomes after Treatment Using Teicoplanin at the Minimum Inhibitory Concentration of >2 μg/mL in Methicillin-resistant Staphylococcus aureus Bacteremia].
    Kagami K; Imai S; Tazawa Y; Iwasaki S; Fukumoto T; Akizawa K; Yamada T; Ishiguro N; Iseki K
    Yakugaku Zasshi; 2018; 138(9):1181-1189. PubMed ID: 30175762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of factors associated with the achievement of an optimal teicoplanin trough concentration
.
    Takechi K; Yanagawa H; Zamami Y; Ishizawa K; Tanaka A; Araki H
    Int J Clin Pharmacol Ther; 2017 Aug; 55(8):672-677. PubMed ID: 28655381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections.
    Nakamura A; Takasu O; Sakai Y; Sakamoto T; Yamashita N; Mori S; Morita T; Nabeta M; Hirayu N; Yoshiyama N; Moroki M; Tashiro K; Kannae M
    J Infect Chemother; 2015 Jun; 21(6):449-55. PubMed ID: 25726436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level.
    Sato M; Chida K; Suda T; Muramatsu H; Suzuki Y; Hashimoto H; Gemma H; Nakamura H
    J Infect Chemother; 2006 Aug; 12(4):185-9. PubMed ID: 16944256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of teicoplanin dosing designs to achieve a new target trough concentration.
    Ueda T; Takesue Y; Nakajima K; Ichki K; Wada Y; Tsuchida T; Takahashi Y; Ishihara M; Tatsumi S; Kimura T; Ikeuchi H; Uchino M
    J Infect Chemother; 2012 Jun; 18(3):296-302. PubMed ID: 22065089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of High Trough Concentration of Teicoplanin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infection.
    Sato Y; Tokimatsu I; Suzuki Y; Itoh H; Hiramatsu K; Kadota J
    Chemotherapy; 2014; 60(4):274-8. PubMed ID: 25926288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin loading dose is associated with increased early clinical response without attainment of initial target trough concentration at a steady state in patients with methicillin-resistant Staphylococcus aureus infections.
    Ueda T; Takesue Y; Nakajima K; Ichiki K; Ishikawa K; Takai Y; Yamada K; Wada Y; Tsuchida T; Otani N; Takahashi Y; Ishihara M; Shibata S; Ikeuchi H; Uchino M; Kimura T
    J Clin Pharm Ther; 2020 Aug; 45(4):682-690. PubMed ID: 32301537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection.
    Ogawa R; Kobayashi S; Sasaki Y; Makimura M; Echizen H
    Int J Clin Pharmacol Ther; 2013 May; 51(5):357-66. PubMed ID: 23458228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus.
    Hagihara M; Umemura T; Kimura M; Mori T; Hasegawa T; Mikamo H
    J Infect Chemother; 2012 Feb; 18(1):10-6. PubMed ID: 21710160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of individual adjustment of initial loading dosage of teicoplanin based on population pharmacokinetics.
    Niwa T; Imanishi Y; Ohmori T; Matsuura K; Murakami N; Itoh Y
    Int J Antimicrob Agents; 2010 May; 35(5):507-10. PubMed ID: 20185275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Therapeutic Drug Monitoring Optimizes Teicoplanin Use in Febrile Neutropenic Patients with Hematological Malignancies.
    Wang YW; Hou HA; Lin CC; Lin HY; Chen PZ; Kuo CH; Chiu HH; Chuang CC; Chen YJ; Lin SW
    Adv Ther; 2024 Jul; 41(7):2966-2977. PubMed ID: 38743241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.